CERO Therapeutics Holdings, Inc. announced on May 8, 2025, that it has regained compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires a minimum stockholders’ equity of $2.5 million, a critical requirement for continued listing on the Nasdaq exchange.
The Nasdaq Hearings Panel notified the company on May 7, 2025, confirming its compliance. This achievement follows a series of financing activities, including the execution of a private placement of Series D Preferred Stock on April 21, 2025, a partial drawdown from the company’s Equity Line of Credit, and the closing of a public offering in February 2025.
CEO Chris Ehrlich stated that having achieved compliance, the company is now poised to focus all its efforts on the progression of its lead program, CER-1236. This milestone is expected to allow CERO Therapeutics to fulfill its goal of becoming a successful clinical-stage biotechnology company developing immunotherapy for cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.